Loading…
JNJ
Johnson & Johnson
NYSE· Healthcare· Drug Manufacturers - General· CUSIP 478160104
$267.61+3.81%Price as of Oct 23, 00:41 UTC · updated once a day, after the close
At a glance
Johnson & Johnson (JNJ) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in New Brunswick, United States and has 138,200 employees. The company is worth $644.91B and trades at 39.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $94.19B in fiscal 2025, up 6.0% from the year before. Net income was $26.8B. The share price is 4.8% below its 52-week high of $281.07. It pays a dividend yielding 2.00%, and has raised its annual dividend for 28 years in a row in our records. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $738.49M. In that quarter, 1 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Analysis
Articles on this site that cover Johnson & Johnson.
- Insider buying and selling, last 90 days: who used their own money, and who sold without a planPublished Oct 22, 2026
- Johnson & Johnson (JNJ): $94 billion of sales, a $5.5 billion talc proposal and 64 years of dividend increasesPublished Oct 13, 2026
- The biggest insider sales of the last 90 days, without the plans, the taxes and the fundsPublished Oct 11, 2026
Key metrics
- Market cap
- $644.91B
- P/E
- 39.1x
- Forward P/E
- 23.0x
- P/B
- 7.6x
- Dividend yield
- 2.00%
- Payout
- 78.36%
- EPS
- $6.84
- ROE
- —
- Profit margin
- 16.20%
- Revenue growth
- +5.90%
- Beta
- 0.21
- 52-week high
- $281.07
- 52-week low
- $184.66
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Cliff AsnessReducedAQR Capital Management · Q2 2026$738.49M2.91M shares · 0.3% of portfolio
Ken GriffinReducedCitadel Advisors · Q2 2026$381.17M1.5M shares · 0.2% of portfolio
Ray DalioReducedBridgewater Associates · Q2 2026$169.94M669.14K shares · 0.7% of portfolio- Tom GaynerHeldMarkel Group · Q2 2026$155.12M610.8K shares · 1.2% of portfolio
- Israel EnglanderAddedMillennium Management · Q2 2026$150.88M594.09K shares · 0.1% of portfolio
Prem WatsaHeldFairfax Financial Holdings · Q2 2026$18.64M73.4K shares · 0.7% of portfolio- Two SigmaReducedTwo Sigma Investments · Q2 2026$8.87M34.91K shares · 0.0% of portfolio
George SorosHeldSoros Fund Management · Q2 2026$8.64M34.02K shares · 0.1% of portfolio
Price over time
▲ +63.9% over 5Y.
today you would have $1,804.13▲ +80.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $206.95 | $144.62 | $156.74 | $176.65 | $171.07 | $157.38 | $145.87 | $129.05 | $139.72 | $115.21 | $102.72 | $104.57 | $91.59 | $70.10 | $65.58 | $61.85 | $64.41 | $59.83 | $66.70 | |
| P/E | 18.8x | 18.8x | 25.0x | 11.4x | 26.2x | 21.9x | 28.6x | 25.9x | 23.0x | 297.3x | 19.4x | 18.7x | 18.3x | 19.0x | 18.2x | 18.8x | 12.9x | 14.6x | 13.1x | 18.4x |
| P/S | 4.0x | 5.3x | 3.9x | 4.4x | 5.8x | 5.7x | 5.0x | 4.7x | 4.2x | 4.9x | 4.3x | 4.0x | 3.9x | 3.6x | 2.9x | 2.8x | 2.7x | 2.9x | 2.7x | 3.2x |
| P/B | 4.5x | 6.1x | 4.9x | 5.5x | 6.0x | 6.1x | 6.5x | 6.5x | 5.8x | 6.2x | 4.4x | 4.0x | 4.2x | 3.5x | 3.0x | 3.2x | 3.0x | 3.5x | 4.0x | 4.5x |
| EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 | |
| Dividend yield | 2.74% | 2.48% | 3.40% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% | 2.64% | 2.83% | 3.42% | 3.43% | 3.41% | 3.00% | 3.00% | 2.43% |
| Payout | 53.83% | 46.60% | 84.80% | 34.26% | 66.12% | 53.65% | 72.23% | 66.61% | 63.10% | 706.38% | 53.12% | 53.83% | 48.42% | 53.85% | 62.18% | 64.47% | 44.14% | 43.86% | 39.28% | 44.63% |
| Profit margin | 19.82% | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% |
| ROE | 23.49% | 32.87% | 19.68% | 51.11% | 23.36% | 28.20% | 23.25% | 25.42% | 25.60% | 2.16% | 23.49% | 21.66% | 23.40% | 18.68% | 16.74% | 16.94% | 23.57% | 24.25% | 30.46% | 24.41% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$73.69
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$115.55
Earnings growing 14.9% a year plus a 2.0% dividend yield. Growth capped at 25%.
Earnings
$166.11
Median P/E of 24.3 among peers in the sector.
Earnings
$128.43
Median P/E of 18.8 across this company’s own years on record.
Cash flow
$264.69
Cash flow growing 14.9% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
$361.51
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $120.95 (avg. of 4)+Cash flow $264.69+Dividends $361.51÷ 3 =$249.05
$249.05
6 methods answered, across 3 families.
$186.79
Room for errors in the reported numbers.
$267.61
-6.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ABBVAbbVie Inc. | $285.19 | 80.6x | — | 2.43% | — | $503.96B |
| UNHUnitedhealth Group Inc | $424.98 | 26.8x | 3.7x | 2.18% | 15.77% | $381.46B |
| MRKMerck & Co., Inc. | $147.24 | 116.9x | 8.7x | 2.31% | 6.96% | $363.27B |
| LLYELI LILLY & Co | $1,306.69 | 42.7x | 34.4x | 0.53% | 102.29% | $1.17T |
| NVSNovartis AG | $156.27 | 23.6x | 7.1x | 3.03% | 30.35% | $297.02B |
| AZNAstrazeneca PLC | $172.57 | 25.8x | 5.3x | 1.85% | 21.96% | $267.64B |
About the company
- 138,200
- New Brunswick, United States